Small molecule ectonucleotide pyrophosphatase/phosphodiesterase 1 inhibitors in cancer immunotherapy for harnessing innate immunity

被引：5
|
作者：
Choi, Junwon [1 ]
机构：
[1] Ajou Univ, Dept Mol Sci & Technol, Suwon, Gyeonggi, South Korea
来源：
BULLETIN OF THE KOREAN CHEMICAL SOCIETY | 2023年 / 44卷 / 02期
基金：
新加坡国家研究基金会;
关键词：
cancer immunotherapy; cGAMP; ENPP1; inhibitor; innate immunity; STING; CYCLIC GMP-AMP; NUCLEOTIDE PYROPHOSPHATASE; EXTRACELLULAR CGAMP; POTENT INHIBITORS; BYSTANDER CELLS; HUMAN NPP1; DERIVATIVES; HYDROLYSIS; 2ND-MESSENGER; ENPP1;
D O I：
10.1002/bkcs.12646
中图分类号：
O6 [化学];
学科分类号：
0703 ;
摘要：
Ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1) was recently identified as a major hydrolase of an endogenous stimulator of interferon genes (STING) agonist, 2 ',3 '-cyclic guanosine monophosphate-adenosine monophosphate (cGAMP). ENPP1 is a promising therapeutic target in cancer immunotherapy, in which the inhibition of ENPP1 enhances anticancer immunity via STING-mediated innate immune activation. This review highlights the role of ENPP1 in innate immunity and the recent discovery of small molecule ENPP1 inhibitors as immunomodulators in cancer immunotherapy.
引用
收藏
页码：88 / 99
页数：12
相关论文
共 50 条
  • [41] Small molecule inhibitors for cancer immunotherapy and associated biomarkers - the current status
    Schlicher, Lisa
    Green, Luke G.
    Romagnani, Andrea
    Renner, Florian
    FRONTIERS IN IMMUNOLOGY, 2023, 14
  • [42] Increased Expression Of Ectonucleotide Pyrophosphatase/phosphodiesterase-1 (enpp-1) In Aortic Stenosis: Implication For The Calcification Of The Aortic Valve
    Pepin, Andres
    Bosse, Yohan
    Pibarot, Philippe
    Charest, Allain
    Mathieu, Patrick
    CIRCULATION, 2008, 118 (18) : S1019 - S1020
  • [43] Exploring innate immunity in cancer immunotherapy: opportunities and challenges
    Li, Xiaolei
    Dai, Hanren
    Wang, Hua
    Han, Weidong
    CELLULAR & MOLECULAR IMMUNOLOGY, 2021, 18 (06) : 1607 - 1609
  • [44] Enhancing Cancer Immunotherapy Via Activation of Innate Immunity
    Goldberg, Jacob L.
    Sondel, Paul M.
    SEMINARS IN ONCOLOGY, 2015, 42 (04) : 562 - 572
  • [45] Exploring innate immunity in cancer immunotherapy: opportunities and challenges
    Xiaolei Li
    Hanren Dai
    Hua Wang
    Weidong Han
    Cellular & Molecular Immunology, 2021, 18 : 1607 - 1609
  • [46] Small molecule inhibitors as adjuvants in cancer immunotherapy: enhancing efficacy and overcoming resistance
    Wu, Xiaolin
    Feng, Nuan
    Wang, Chao
    Jiang, Hongfei
    Guo, Zhu
    FRONTIERS IN IMMUNOLOGY, 2024, 15
  • [47] Potent and selective small molecule USP7 inhibitors for cancer immunotherapy
    Kumar, Suresh
    Wu, Jian
    Wang, Liqing
    Wang, Jack
    Sokirniy, Ivan
    Wang, Hui
    Fegley, Glen
    Weinstock, Joseph
    Mattern, Michael
    Hancock, Wayne W.
    CANCER IMMUNOLOGY RESEARCH, 2016, 4 (11)
  • [48] Small-molecule Cbl-b inhibitors as novel intracellular checkpoint inhibitors for cancer immunotherapy
    Riling, Christopher
    Sokirniy, Ivan
    Cunnion, Brigid
    Todd, Emily
    Mattern, Michael
    Wu, Jian
    Kambayashi, Taku
    Kumar, Suresh
    MOLECULAR CANCER THERAPEUTICS, 2018, 17 (01)
  • [49] Ecto-nucleotide pyrophosphatase/phosphodiesterase 1 inhibitors: Research progress and prospects
    Guan, Dezhong
    Fang, Lincheng
    Feng, Mingshun
    Guo, Shi
    Xie, Lingfeng
    Chen, Chao
    Sun, Xue
    Wu, Qingyun
    Yuan, Xinrui
    Xie, Zuoquan
    Zhou, Jinpei
    Zhang, Huibin
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2024, 267
  • [50] Design, synthesis and biological evaluation studies of novel small molecule ENPP1 inhibitors for cancer immunotherapy
    Gangar, Mukesh
    Goyal, Sandeep
    Raykar, Digambar
    Khurana, Princy
    Martis, Ashwita M.
    Goswami, Avijit
    Ghoshal, Ishani
    Nagare, Yadav
    Raikar, Santosh
    Mukherjee, Apurba
    Cyriac, Rajath
    Paquin, Jean-Francois
    Kulkarni, Aditya
    Patel, Ketul, V
    BIOORGANIC CHEMISTRY, 2022, 119
12345